Blueprint Medicines Corporation
NASDAQ:BPMC
86 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 249.38 | 204.036 | 180.08 | 793.735 | 66.512 | 44.521 | 21.426 | 27.772 | 11.4 | 0 | 0 |
| Cost of Revenue
| 24.461 | 17.813 | 17.934 | 0.425 | 0 | 243.621 | 144.687 | 81.131 | 48.588 | 31.844 | 15.928 |
| Gross Profit
| 224.919 | 186.223 | 162.146 | 793.31 | 66.512 | -199.1 | -123.261 | -53.359 | -37.188 | -31.844 | -15.928 |
| Gross Profit Ratio
| 0.902 | 0.913 | 0.9 | 0.999 | 1 | -4.472 | -5.753 | -1.921 | -3.262 | 0 | 0 |
| Reseach & Development Expenses
| 416.055 | 477.419 | 601.033 | 326.86 | 331.45 | 243.621 | 144.687 | 81.131 | 48.588 | 31.844 | 15.928 |
| General & Administrative Expenses
| 278.241 | 219.274 | 181.793 | 148.343 | 96.388 | 47.928 | 27.986 | 19.218 | 14.456 | 7.89 | 5.072 |
| Selling & Marketing Expenses
| 16.9 | 18.1 | 13.5 | 9.4 | 3.3 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 295.141 | 237.374 | 195.293 | 157.743 | 96.388 | 47.928 | 27.986 | 19.218 | 14.456 | 7.89 | 5.072 |
| Other Expenses
| -0.946 | 8.948 | 7.801 | -0.366 | -0.1 | 10.459 | 3.349 | 0.551 | -0.429 | -0.098 | 0.226 |
| Operating Expenses
| 711.196 | 723.741 | 804.127 | 484.603 | 427.838 | 291.549 | 172.673 | 100.349 | 63.044 | 39.734 | 21 |
| Operating Income
| -486.277 | -549.253 | -648.46 | 302.148 | -366.585 | -247.028 | -149.476 | -73.608 | -53.021 | -39.832 | -20.774 |
| Operating Income Ratio
| -1.95 | -2.692 | -3.601 | 0.381 | -5.512 | -5.549 | -6.976 | -2.65 | -4.651 | 0 | 0 |
| Total Other Income Expenses Net
| -19.739 | -3.028 | 7.376 | 12.792 | 18.891 | 10.459 | 3.349 | 0.551 | -0.429 | -0.098 | 0.226 |
| Income Before Tax
| -506.016 | -552.281 | -641.084 | 314.94 | -347.694 | -236.642 | -148.119 | -72.495 | -52.769 | -40.285 | -20.912 |
| Income Before Tax Ratio
| -2.029 | -2.707 | -3.56 | 0.397 | -5.228 | -5.315 | -6.913 | -2.61 | -4.629 | 0 | 0 |
| Income Tax Expense
| 0.968 | 5.236 | 3.001 | 1.058 | -18.991 | 10.459 | 1.992 | -0.562 | -0.681 | 0.355 | 0.364 |
| Net Income
| -506.984 | -557.517 | -644.085 | 313.882 | -328.703 | -236.642 | -148.119 | -72.495 | -52.769 | -40.285 | -20.912 |
| Net Income Ratio
| -2.033 | -2.732 | -3.577 | 0.395 | -4.942 | -5.315 | -6.913 | -2.61 | -4.629 | 0 | 0 |
| EPS
| -8.37 | -9.35 | -11.01 | 5.76 | -6.87 | -5.39 | -3.92 | -2.64 | -2.89 | -3.08 | -1.6 |
| EPS Diluted
| -8.37 | -9.35 | -11.01 | 5.59 | -6.87 | -5.39 | -3.92 | -2.64 | -2.89 | -3.08 | -1.6 |
| EBITDA
| -474.612 | -537.518 | -641.981 | 308.707 | -361.326 | -236.569 | -147.898 | -72.026 | -52.073 | -39.21 | -20.273 |
| EBITDA Ratio
| -1.903 | -2.634 | -3.565 | 0.389 | -5.432 | -5.314 | -6.903 | -2.593 | -4.568 | 0 | 0 |